AgomAb Therapeutics N.V. American Depositary Shares Long Term Debt

AgomAb Therapeutics N.V. American Depositary Shares posts a long-term debt of $910K as of June 2026. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

Long-Term Debt is one piece of AgomAb Therapeutics N.V. American Depositary Shares's financial statement story. At $910K, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for AGMB's long-term debt usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; AgomAb Therapeutics N.V. American Depositary Shares's other metric pages and overview cover the third.

Judging AgomAb Therapeutics N.V. American Depositary Shares against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in long-term debt easier to interpret. Start with $910K here, then scan peer and history charts to see if the gap is persistent.